REPLY
18.5.2021 09:32:11 CEST | Business Wire | Press release
Through its proprietary Trend Sonar trend monitoring platform, Reply recently conducted a study to examine how the e-commerce model has evolved over time – particularly in the automotive domain – revolutionising the sector and consequently influencing customer expectations.
A digital approach and a strong online presence have become indispensable in the automotive sector, especially since last year when the global pandemic placed the digital realm in a preferential lane, rewarding businesses that have been able to change their business model quickly in favour of digitisation.
Over the past year (more specifically from April 2020 to March 2021), analysing the frequency of mentions of millions of online sources – expert media articles, mass media, patents and scientific publications – Reply’s Trend Sonar monitoring platform has, indeed, confirmed a 61% growth in content related to automotive e-commerce compared to the previous 12 months.
An evolution that starts from afar. The automotive sector is not new to change: in the last 20 years it has been the protagonist of an unprecedented revolution. Reply’s analysis, in fact, shows that all the conditions and prerequisites are in place for the sector to find itself on the threshold of a new discontinuity.
The first online marketplaces for used cars date back to 2000, while a few years later the first online broker platforms began gaining popularity, directly connecting authorised dealers and end consumers and offering online booking, car configuration and digital brochure services. This was followed by the first online dealerships and, in recent years, car manufacturers have started selling their vehicles directly to the end consumer, adopting Direct to Consumer models.
Today's scenario: between the physical and the digital worlds. With the Covid-19 pandemic, the pace of digitalisation has greatly accelerated: digitised analytics systems, pricing tools and financing processes are now a necessary standard to help increase leads in the sector. Reply’s study highlights precisely how, at this point in time, we find ourselves at a crossroads between the offer of digital and traditional services. Indeed, in the near future, services such as 3D showrooms, virtual test drives, advanced configuration tools and digital concierge services are expected to see increasing use, allowing consumers to test and configure products directly online.
By opting for direct online sales to customers, native digital car manufacturers are turning the traditional car buying model upside down. The customer journey has also been impacted by the current revolution underway: leasing, financing, choice of insurance providers and coverage or even vehicle registration have recently digitised and automated the customer experience, shortening waiting times and eliminating paper documents.
The future of mobility is increasingly more virtual. Since car sharing services have entered the market, mobility has, in fact, begun to be perceived as a service built around the digital world . Many car manufacturers and industry suppliers are adopting an approach in which the car is becoming a platform capable of providing access to a broad digital ecosystem of app-based data and services. In fact, in the future, in addition to a means of mobility and transport, cars are expected to be increasingly used as a tool to collect data on customers. Access, exchange and sharing of this information will be decisive for defining future dynamics and for offering the customer a range of more complete and personalised services, which may even include solutions proposed by customers themselves.
More information on the research is available on Reply’s website at “E-commerce trends: mobility and car sales ”.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005081/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom